283. Acquired pure red cell aplasia Clinical trials / Disease details

Clinical trials : 18 / Drugs : 42 - (DrugBank : 22) / Drug target genes : 19 - Drug target pathways : 98

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04470804 (ClinicalTrials.gov)	August 1, 2020	9/7/2020	Sirolimus Treatment for Newly Diagnosed Primary Acquired PRCA	Sirolimus Treatment for Newly Diagnosed Primary Acquired Pure Red Cell Aplasia: a Single Center Prospective Study	Pure Red Cell Aplasia, Acquired	Drug: Sirolimus;Drug: Cyclosporine A	Bing Han	NULL	Recruiting	18 Years	70 Years	All	40	Phase 4	China
2	NCT01288131 (ClinicalTrials.gov)	January 2009	1/2/2011	Study of Anti-r-HuEpo Associated Pure Red Cell Aplasia (PRCA) Treatment	Randomized Controlled Trial Study of Anti-r-HuEpo Associated PRCA Treated by Cyclosporine and Mycophenolate Mofetil (MMF) Compared With Cyclophosphamide and Prednisolone	Anti-r-HuEpo Associated PRCA Subjects	Drug: Cyclosporine combine with mycophenolate mofetil;Drug: Cyclophosphamide + pred	Chulalongkorn University	NULL	Terminated	18 Years	60 Years	Both	8	Phase 3	Thailand